OCA, as the other members of FXR agonists family, may exert multiple therapeutic effects on NASH by improving hepatic lipid and glucose metabolism and through its anti-inflammatory and anti-fibrotic activity. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.